LGMD arises from mutations in genes encoding structural, enzymatic, or glycosylation-pathway proteins critical to muscle membrane integrity and function. Genetic heterogeneity accounts for the wide clinical spectrum observed across subtypes. Specific causative genes are not listed in the certified packet for this umbrella disease entry.

Diagnostic evaluation includes clinical assessment, serum creatine kinase measurement, electrophysiological testing, muscle imaging, and muscle biopsy. Genetic panel testing is central to subtype classification and identification of the underlying molecular cause.

No FDA-approved medications are listed in the certified packet for LGMD as a category. Management addresses symptoms and complications, including physical and respiratory support. Multiple gene therapy and molecular treatment approaches are under active clinical investigation for specific genetic subtypes.

Prognosis varies substantially across LGMD subtypes and depends on the underlying genetic cause, rate of disease progression, and presence of cardiac or respiratory involvement. Disease trajectories range from slowly progressive to earlier functional decline.

Active clinical investigations include Phase 3 gene transfer trials for specific LGMD subtypes, Phase 3 ribitol supplementation trials for LGMD R9/2I, Phase 1 gene therapy studies, and multiple international natural history registries characterizing the LGMD spectrum.